All In Biotech

Drug Trial Radar · NCT01807949

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Last checked: Nov 19, 2026Latest source record: Sep 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 563 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

563

Actual

Start

Apr 2013

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Mar 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.

Conditions

  • Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Interventions

  • PlaceboDrug

    Matching placebo tablet

  • Lumacaftor Plus Ivacaftor CombinationDrug

    Fixed dose combination tablet

  • IvacaftorDrug

    Film-coated tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24Time frame: Baseline, Week 16 and 24

Locations

82 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Oakland, California

  • Site not named

    Sacramento, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Hartford, Connecticut

  • Site not named

    New Haven, Connecticut

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Kansas City, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Portland, Maine

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Jackson, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Morristown, New Jersey

  • Site not named

    New Brunswick, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Albany, New York

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Syracuse, New York

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Toledo, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Sioux Falls, South Dakota

  • Site not named

    Memphis, Tennessee

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Fort Worth, Texas

  • Site not named

    Houston, Texas

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.